Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.
Diffuse Large B Cell Lymphoma
DRUG: Yangzhengxiaoji capsule combined with CHOP regimen|DRUG: CHOP regimen
Progression-free survival, up to end of follow-up-phase (approximately 24 months)
overall survival, up to the date of death (approximately 5 years)
The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.